Navigation Links
Techne Corporation Announces Acquisition Agreement
Date:6/18/2013

control products and is developing new controls for other growing diagnostic uses, particularly controls for cholesterol and HbA1c point-of-care testing (POCT) devices. Bionostics is positioned to take advantage of continuing growth driven by the increasing prevalence of diabetes and other diseases, the migration of diagnostic testing from the laboratory to the operating room, bedside, clinic, and home points of care, the implementation of controls regulations in global markets and new controls being required for emerging diagnostic and (POCT) products.

Bionostics has a strong track record of profitable, cash generative growth with revenues of approximately $29.3 million for its fiscal year ended August 31, 2012. Its adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) were approximately $9.4 million in its fiscal year ended August 31, 2012 for an EBITDA margin of approximately 32%.  EBITDA adjustments include Bionostics' Board of Director fees, transaction related costs and severance payments that will not recur after the acquisition.

Bionostics will be acquired for $104 million in cash, subject to adjustment following closing based on the final level of working capital of Bionostics.  The acquisition is expected to be slightly accretive to Techne's fiscal year 2014 net earnings, despite the impact of acquisition accounting related to the step-up in basis for acquired inventories and the amortization of intangibles.  However, the purchase price allocation of the acquisition has not been completed and, therefore, it is not currently possible to predict the impact that the acquisition will have on first quarter fiscal 2014 or fiscal 2014 earnings per share.

Charles R. Kummeth, President and Chief Executive Officer of Techne, said, "We are delighted to add the Bionostics team to our Hematology division. This business is how Techne R&D Systems was founded some 30 years ago
'/>"/>

SOURCE Techne Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Techne Corporation Releases Unaudited Third Quarter And Nine Month Fiscal Year 2013 Results
2. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
3. Techne Corporation Declares Dividend And Announces An Increase In Its Share Repurchase Program
4. Techne Corporation Declares Dividend
5. China Cord Blood Corporation to Report Fourth Quarter and Full Year of Fiscal 2013 Financial Results
6. Celsion Corporation Announces $9.83 Million Registered Direct Offering
7. Sigma-Aldrich Corporation Presentations At Three Upcoming Conferences To Be Webcast Live
8. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
9. The Renewable Corporation (RNWB) through its wholly owned subsidiary EcoSmart Surface & Coating Technologies receives results from Product Test Service.
10. Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal
11. Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Global Resorcinol Market 2015-2019 ... insights on the global resorcinol industry. The report highlights the various growth prospects ... scenarios and analysis of primary and secondary inputs from the existing players of ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud to announce ... gluten in foods, has been accepted by AOAC International as Official First Action ... Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal antibody ...
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... appointed Francois Vieillard as Sales & Marketing Director. , With more than ... will be responsible for reinforcing Tronics’ business development activities worldwide. He brings to ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... Interleukin Genetics, Inc. (OTC QB: ILIU) announced today that ... Showcase 2011, taking place at the Parc 55 Wyndham ... include a company overview highlighting its business opportunities and ... in the Mission II room.   Company ...
... Jan. 4, 2011 Reportlinker.com announces that a ... catalogue: Emerging Opportunities and ... r Diagnostics Market: US, ... http://www.reportlinker.com/p0357263/The-2011-Cancer-Diagnostics-Market-US-Europe-Japan ...
... , a division of BNA , announces the publication ... of Biotechnology and the Federal Circuit , the only ... body of Federal Circuit precedent in the rapidly developing area ... Biotechnology and the Federal Circuit, Second Edition ...
Cached Biology Technology:Interleukin Genetics, Inc. to Present at Biotech Showcase 2011 2Reportlinker Adds The 2011 Cancer Diagnostics Market: US, Europe, Japan Emerging Opportunities and Business Expansion Strategies 2New Second Edition of Biotechnology and the Federal Circuit Examines the Court's Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases 2New Second Edition of Biotechnology and the Federal Circuit Examines the Court's Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases 3New Second Edition of Biotechnology and the Federal Circuit Examines the Court's Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases 4
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... PHILADELPHIA - The University of Pennsylvania,s Laboratory ... entered into a multi-year agreement with specialty chemical ... Scientific Research to launch an international, public-private research ... between academia, government and industry brings together a ...
... Providence, RI Researchers at Rhode Island Hospital have discovered ... injury. The findings shed new light on how the body ... as microvesicles, and offers hope for tissue regeneration. The paper ... Experimental Hematology and is now available online in ...
... mouse colon cancer cells, may help identify patients at ... study by Vanderbilt-Ingram Cancer Center researchers. The findings, ... could help personalize treatments for colon cancer the ... States by identifying patients most likely to benefit ...
Cached Biology News:Penn joins international collaboration in government and academics to research 'soft matter' 2Offering hope for tissue regeneration 2Offering hope for tissue regeneration 3Gene signature may improve colon cancer treatment 2Gene signature may improve colon cancer treatment 3
... is an easy-to-use siRNA transfection reagent that ... genes in a variety of cell lines. ... an optimized, straightforward protocol. High levels of ... following transfection of 20 to 100 nM ...
... tetramethylrhodamine-conjugated jetSI-ENDO (excitation at 555 ... the powerful siRNA transfection reagent. ... determine the transfection efficiency or ... trafficking of siRNAs. More than ...
... in a Morris Water Maze. Tracks up ... sequence of trials.The Spatial Behavior line is a ... camera, frame grabber, and feature extraction software and ... up to 6 moving animals. Software automatically ...
... systems for cultivation of microorganisms and human ... bio-pharmaceutical products maximum performance and economy for ... cell fermentation 10 L 1,500 L. ... ,*Fully automated control system ,*High-quality components ...
Biology Products: